Influx HealthtechNSE:INFLUX -0.65%32 Gross Margin % is 38.61% as of Mar. 2026, which is 41% above its 10-year median of 27.43. GuruFocus rates NSE:INFLUX with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, Influx Healthtech ranks worse than 63.63% on this metric.
The historical rank and industry rank for Influx Healthtech's Gross Margin % or its related term are showing as below:
NSE:INFLUX'
s Gross Margin % Range Over the Past 10 Years
Min: 18.44 Med: 27.43 Max: 40.96
Current: 40.96
During the past 5 years, the highestGross Margin % of Influx Healthtech was 40.96%. The lowest was 18.44%. And the median was 27.43%.
NSE:INFLUX's Gross Margin % is ranked worse than 63.63% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:INFLUX: 40.96
Influx Healthtech had a gross margin of 38.61% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Influx Healthtech was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Influx Healthtech had a gross margin of 38.61% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Influx Healthtech Gross Margin % Related Terms
Influx Healthtech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INFLUX vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Influx Healthtech (NSE:INFLUX) has a Gross Margin % of 38.61% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Influx Healthtech and its competitors. This is 41% above median its historical median of 27.43. Over the past decade, Influx Healthtech's Gross Margin % has ranged from 18.44 to 40.96. According to the industry distribution chart, Influx Healthtech ranks #600 out of 943 companies in the Drug Manufacturers industry, placing it in the top 63.6%.
Is Influx Healthtech's Gross Margin % too high?
Influx Healthtech's current Gross Margin % of 38.61% is 41% above median its 10-year median of 27.43. Over the past 10 years, this metric has ranged from a low of 18.44 to a high of 40.96. The Drug Manufacturers industry median Gross Margin % is 48.54. Influx Healthtech's value of 38.61% is 20.5% below this industry median. Based on the distribution chart, Influx Healthtech ranks #600 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Influx Healthtech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #600 out of 943 companies for Gross Margin %. This places Influx Healthtech in the lower half of its industry. The industry median Gross Margin % is 48.54. Influx Healthtech's value of 38.61% is 20.5% below this benchmark. Historically, Influx Healthtech's own Gross Margin % has ranged from 18.44 to 40.96 over the past decade. While the company's 10-year median is 27.43 vs. the industry median of 48.54, Influx Healthtech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current Gross Margin % of 38.61% is 20.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current Gross Margin % is 38.61%, which is 41% above median its own 10-year median of 27.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Gross Margin % of 38.61%. The current Gross Margin % is 38.61%, which is 41% above median its 10-year median of 27.43 and 20.5% below the Drug Manufacturers industry median of 48.54. Influx Healthtech's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Gross Margin % is 38.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
32GF Score
Get the complete analysis for NSE:INFLUX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 